Synklino ApS Appoints Tolga Hassan as CFO and Dr. Josefin-Beate Holz as CMO

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

October 28, 2020

Synklino ApS has appointed Tolga Hassan as Chief Financial Officer and Dr. Josefin-Beate Holz as Chief Medical Officer. This announcement follows the recent closing of a financing round led by Eir Ventures and Vaekstfonden.

Synklino ApS Co-founder and Chief Executive Officer Thomas Kledal said, “We are very pleased to attract high caliber individuals who have the unique expertise to support Synklino on its very ambitious journey. Josi’s knowledge and experience in clinical research will be invaluable as we advance our lead program towards clinical testing. Tolga’s finance and transactional experience will be important as the company moves to its next stage of growth. I’m very pleased to have Josi and Tolga join us in our mission to provide patients a chance to live a full life after transplantation.”

Tolga brings over 25 years of strategic financial management and corporate structuring experience. His recent roles include board level CFO and COO positions at F-star Therapeutics where he was involved in the financing, discovery and business development efforts that led F-star Therapeutics into a clinical-stage, NASDAQ-ready biotech company and where he was responsible for concluding a series of licensing and collaboration agreements with global pharmaceutical companies. Tolga’s previous roles include Director of Corporate Development at FTSE-listed specialty chemical company Johnson Matthey plc. and various valuation and transaction advisory roles at Andersen. Tolga holds an MA in Economics from the University of Cambridge and is a qualified Chartered Accountant.

Josi has over 25 years’ experience in pharmaceutical drug development in Europe and North America. She has held executive managerial positions at international pharmaceutical & biotech companies Ablynx, GPC-Biotech, Gilead Sciences, Bristol-Myers Squibb and LEO Pharma. Dr. Holz has worked on more than 50 disease targets at various stages of clinical validation across oncology, immunology and other indications. She is a medical advisor to the European Commission and is member of various medical associations such as ASCO, ESMO and SITC. She provides clinical advice and part-time CMO support for SMEs and biotech companies. Dr. Holz received her PhD in Haematology Oncology from the University Marburg in 1995.

The management team will be presenting at the upcoming LSX Investival Showcase, 11-16 November 2020 and are available to meet investors and potential partners.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.